United Kingdom  

Gilead sparks Wall Street rally

Video Credit: Reuters Studio - Duration: 01:20s - Published
Gilead sparks Wall Street rally

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States.

Fred Katayama reports.

0
shares
ShareTweetSavePostSend
 

💡 One News Page Knowledge: Other News Mentions

Gilead Sciences American pharmaceutical company

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead says remdesivir cuts death risk [Video]

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:04Published
Gilead's remdesivir gets conditional EU clearance [Video]

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

Credit: Reuters Studio    Duration: 00:59Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published

Wall Street Wall Street Street in Manhattan, New York

AMC Theatres, Universal Pictures Forge Historic Deal Allowing Theatrical Releases to Debut on Premium VOD | THR News [Video]

AMC Theatres, Universal Pictures Forge Historic Deal Allowing Theatrical Releases to Debut on Premium VOD | THR News

Wall Street analysts on Wednesday weighed in on AMC Theatres' historic agreement with Universal Pictures that will allow the studio's movies to be made available on premium video-on-demand after just 17 days of play in cinemas.

Credit: The Hollywood Reporter    Duration: 01:27Published
Shopify Crushes Q2 Expectations [Video]

Shopify Crushes Q2 Expectations

On Wednesday, Shopify reported second-quarter earnings results that beat Wall Street's expectations for revenue. The company surged 97% on the year as the coronavirus pandemic boosted online sales. Shares of Shopify surged as much as 12% Wednesday. Business Insider reports the Canadian e-commerce company has gained roughly 170% year-to-date.

Credit: Wochit News    Duration: 00:29Published
Jobless spike, stimulus fight spark stock drop [Video]

Jobless spike, stimulus fight spark stock drop

Wall Street dropped sharply on Thursday as investors fretted over the first weekly jump in jobless claims in months and a battle in Congress over the extension of a special unemployment payout. Conway G. Gittens has the action.

Credit: Reuters Studio    Duration: 01:52Published
Wall Street ends choppy session higher [Video]

Wall Street ends choppy session higher

Wall Street ended higher on Wednesday after a see-saw session as investors digested mixed quarterly results and contentious stimulus negotiations in Washington. This report produced by Yahaira Jacquez.

Credit: Reuters Studio    Duration: 01:49Published
Obama: Dodd-Frank act protected people on 'Main Street' [Video]

Obama: Dodd-Frank act protected people on 'Main Street'

On the 10th anniversary of the Dodd-Frank Act, which former President Barack Obama's administration helped enact in his first term, Obama on Tuesday said the act protected Americans from being devastated by Wall Street "ever again."

Credit: Reuters Studio    Duration: 01:35Published

Coronavirus disease 2019 Coronavirus disease 2019 Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2

Matt Hancock announces new Covid-19 testing programme [Video]

Matt Hancock announces new Covid-19 testing programme

Matt Hancock has announced two tests which can detect coronavirus and flu are to be rolled out. The tests promise results in 90 minutes and can even be conducted by people without medical training. Report by Etemadil. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn

Credit: ODN    Duration: 00:53Published
Seasonal Flu Reports Drop to Record Lows Amid Social Distancing Measures [Video]

Seasonal Flu Reports Drop to Record Lows Amid Social Distancing Measures

Early global influenza figures show how COVID-19 safety measures have also impacted other diseases spread by person-to-person contact.

Credit: Cover Video STUDIO    Duration: 01:00Published
Lena Dunham still experiencing health problems from Covid-19 battle in March [Video]

Lena Dunham still experiencing health problems from Covid-19 battle in March

Lena Dunham has written about the lasting impact of her battle with Covid-19.

Credit: Cover Video STUDIO    Duration: 00:47Published
Covid-19 testing: The different types and why is it so important? [Video]

Covid-19 testing: The different types and why is it so important?

The Government has announced two new tests for coronavirus and flu, which canreturn results in just 90 minutes, are to be deployed in hospitals, care homesand laboratories from next week. The tests have been hailed as a crucialinstrument in the fight against the pandemic, especially as the UK heads intothe colder months. There are two types of test; the swab test and the finger-prick test, used to test if a person has Covid-19 or once had the virus. Thetwo current test available has some setbacks, mainly being the amount of timeit takes to process results, between 24-72 hours to get results. The mainthing with the news test, yet to be introduced, is the speed with which theyare able to detect not just Covid-19, but also other seasonal illnesses. Thiswill be crucial as Britain heads into winter, as will easily identify ifsufferers will need to self-isolate.

Credit: PA - Press Association STUDIO    Duration: 02:30Published

Fred Katayama journalist

Nasdaq surges on megacap earnings [Video]

Nasdaq surges on megacap earnings

The Nasdaq jumped more than 1% on Friday, powered by strong earnings from some of the largest U.S. companies, but the Dow and S&P finished with smaller gains as uncertainty about the government's next round of coronavirus aid kept economic worries on the radar. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:27Published
Don't chase gold, silver rally: strategist [Video]

Don't chase gold, silver rally: strategist

Susquehanna Investment Group's Chris Murphy says more and more people are chasing the huge rally in gold and silver. He tells Reuters' Fred Katayama there are better options for hedging inflation.

Credit: Reuters Studio    Duration: 04:13Published
Fed will reassure markets - economist [Video]

Fed will reassure markets - economist

Spartan Capital Securities' Peter Cardillo expects the Fed to say it'll do "whatever it takes" to keep adding liquidity to the markets when policymakers meet this week. But he also tells Reuters' Fred Katayama that he thinks there's a good chance the markets will pull back, regardless of the Fed, because "the economy is faltering."

Credit: Reuters Studio    Duration: 04:14Published
Hasbro revenue plunges despite strong demand [Video]

Hasbro revenue plunges despite strong demand

Hasbro reported a sharp drop in revenue Monday, as production shutdowns due to the COVID-19 pandemic crimped the toymaker's efforts to cash in on strong demand for its board games. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:08Published
Market correction is likely: strategist [Video]

Market correction is likely: strategist

Invesco's Brian Levitt says the equities market will likely face a correction or volatility in the near term. But he also tells Reuters' Fred Katayama a new market cycle has emerged where stocks will benefit from improved economic activity and low rates over the longer term.

Credit: Reuters Studio    Duration: 04:47Published

You Might Like


Tweets about this